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B-ALL  B cell acute lymphoblastic leukaemia
CLP  Common lymphoid progenitor
CML  Chronic myelogenous leukaemia
CMP  Common myeloid progenitor
ES  Embryonic stem
GMP  Granulocyte–macrophage progenitor
HSC  Haematopoietic stem cell
LMPP  Lymphoid-primed multipotent progenitor
MPP  Multipotent progenitor
polyI:C  Polyinosinic/polycytidylic acid
PreMegE  Premegakaryocytic/erythroid
VEC  VE-cadherin
Introduction
Cancer is the top fatal disease in the paediatric population 
and now shares the first place in adults with heart disease 
[1]. It is a multifactorial disease that is influenced by genet-
ics (e.g. chromosomal translocations, point mutations and 
single nucleotide polymorphisms), lifestyle (e.g. tobacco 
consumption and obesity), exposure to environmental fac-
tors (e.g. sunlight, radiation and infectious agents) and aging 
[2–4]. Over a lifetime, humans acquire a combination of 
genetic insults. Depending on the genetic insults and the 
cell-of-origin, this translates into the development of a spo-
radic cancer (~90% of cancers).
The scientific community has noted a continued increase 
of sporadic cancers in the paediatric population since the 
1970s. This increase is strikingly restricted to developed 
countries, suggesting that our lifestyle plays a significant 
role in cancer development. Epidemiological factors that 
have been linked to an increased risk of developing paediat-
ric B cell acute lymphoblastic leukaemia (B-ALL) include 
pesticides [5], magnetic exposure [6] and an overstimulation 
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of the immune response during the first years of life (popula-
tion-mixing and delayed-infection hypothesis) [7–9]. B-ALL 
accounts for 26% of cancers diagnosed in children aged 
0–14 years old [10], making it one of the most prevalent can-
cers in the paediatric population. This disease leads to the dif-
ferentiation arrest of B lymphoid cells at an immature stage 
(progenitor or precursor), followed by an uncontrolled pro-
liferation and accumulation of leukaemia blasts in the bone 
marrow. These pro/pre-B leukaemia blasts will migrate from 
the bone marrow to the peripheral circulation to infiltrate 
the spleen, liver, thymus, lymph nodes and central nervous 
system. This hijack of the haematopoietic system by leukae-
mia blasts also compromises the production of other essen-
tial blood cell types for oxygen transport (erythrocytes) or 
coagulation (platelets). This leads to major insufficiencies in 
the patient’s immunological and physiological system, which 
ultimately results in death. Early signs of the disease include 
fatigue, loss of appetite, bone pain, swelling in the abdo-
men (due to splenomegaly and hepatomegaly) and swelling 
of the lymph nodes. Acute leukaemia has a rapid progression 
(weeks) compared to chronic leukaemia (months).
Therapies for B-ALL have greatly improved since the 
1970s when the survival rate was only 10% [11]. Today, at 
least 90% of paediatric patients and 40% of adult patients 
will recover from this disease [12]. This treatment suc-
cess is explained by breakthroughs in understanding the 
molecular mechanisms of leukaemogenesis, leading to 
the development of efficient and specific therapies and the 
use of stem-cell transplantation. The biology of B-ALL is 
determined mainly by the first genetic hit, which is usu-
ally a change in chromosome numbers (hyperdiploidy or 
hypodiploidy) or a chromosomal translocation (e.g. t(4;11) 
MLL-AF4 or t(12;21) ETV6-RUNX1) (Table 1). In pae-
diatric patients, this genetic insult can have an in utero 
origin that can be traced back to birth by analysing the 
Guthrie cards which contain newborn blood spots [13]. 
Increasing evidence suggests that additional genetic events 
are required for leukaemia development, which will be 
described in each section. Furthermore, patients at relapse 
show deletions at specific loci (e.g. CDKN2A/B, ETV6, 
IKZF1, NR3C1) [14]. Some patients also acquire muta-
tions in NT5C2, leading to drug-resistance [15], and in 
CREBBP which impairs the acetylation and transcriptional 
regulation of CREBBP-target genes [16].
This review will explore the biological mechanisms that are 
affected by four chromosomal translocations: t(4;11) MLL-
AF4, t(12;21) ETV6-RUNX1, t(1;19) E2A-PBX1 and t(9;22) 
BCR-ABL1. The first three are associated with perturbations 
in the gene expression profile, whereas t(9;22) BCR-ABL1 
hijacks signalling pathways. Since the members of each trans-
location are involved in normal haematopoiesis, we will also 
describe their role in a physiological situation. We have cho-
sen to focus on these four subclasses as they cover around 
40% of B-ALL patients in children and adults (and 80% in 
infants) and they have been well studied in patients and animal 
models. However, for completeness’ sake, we will also briefly 
mention other subtypes: including hyperdiploidy, hypodip-
loidy, trisomy 4 and 10 and intraamplification of chromosome 
21. In addition, the therapeutic avenues currently available in 
the clinic will be discussed and potential new agents high-
lighted that are in clinical trials (Table 2).
The fast and the furious: t(4;11)(q21;q23) 
MLL‑AF4
Clinical features of MLL‑AF4+ patients
The rearrangement of the MLL gene (11q23) is a common 
genetic event in haematological malignancies [17]. It is 
Table 1  Subtypes of B cell 
acute lymphoblastic leukaemia 
and their frequencies within 
specified age groups
Cytogenetic abnormality Frequency (%) Prognosis
Infant (<1 year 
old)
Children 
(2–18 years old)
Adult 
(>18 years old)
t(4;11)(q21;q23) MLL-AF4 50–85 2–20 10 Poor
t(12;21)(p13;q22) ETV6-RUNX1 Rare 15–12 2 Good
ETV6-RUNX1-like Rare 6 Rare Good
t(1;19)(q23;p13) E2A-PBX1 Rare 2–6 3 Good
t(9;22)(q34;q11.2) BCR-ABL1 Rare 1–3 25 Poor
BCR-ABL1-like Rare 15–20 30–40 Poor
DUX4-rearranged Rare 8 Rare Good
Hyperdiploidy Rare 20–30 7 Good
Hypodiploidy Rare 1–2 2 Poor
Trisomy 4 and 10 Rare 20–25 Rare Very good
Intrachromosomal amplification of 
chromosome 21 (iAMP21)
Rare 2–3 11 Poor
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present in around 10% of ALL and 5% of acute myeloid 
leukaemia (AML). There are more than 80 genes that can 
form chromosomal translocations with the MLL gene in leu-
kaemia, with AF4, AF9 and ENL amongst the most common. 
MLL-rearrangements are found in both paediatric and adult 
ALL, but the prognosis is poorer in childhood ALL regard-
less of the age at diagnosis [18]. Around 50% of patients 
diagnosed with pro-B ALL aged 6 months or less harbour 
the t(4;11) MLL-AF4 chromosomal rearrangement [19]. 
The frequency of t(4;11) MLL-AF4 ALL decreases in older 
infants (10–20%) and drops to just 2% in children. In adult 
B-ALL, it accounts for around 10% of cases.
t(4;11)+ leukaemia is associated with an increased leu-
kocyte count due to an accumulation of leukaemia blasts 
with a phenotype similar to progenitor B cells (negative for 
CD10) [18]. The leukaemia blasts often co-express haema-
topoietic progenitor markers (CD34), B lymphoid mark-
ers (CD19, CD22, CD79a, Tdt), myeloid markers (CD15, 
CD65) and components of the leukocyte antigen complex 
(HLA-DR) [20]. They are negative for CD24, IgM, CD13 
and CD33. A significant proportion of adult and paediatric 
patients express the neural glial marker NG2 on blast cells 
[21, 22], which is also detected in t(12;21) ETV6-RUNX1 
B-ALL and t(9;11) MLL-AF9 AML [23]. Interestingly, the 
NG2 antigen is not expressed in haematopoietic stem cells 
derived from adult bone marrow or neonatal cord blood, 
but is expressed in more mature haematopoietic progenitor 
cells [23, 24].
An interesting feature of t(4;11)+ infant patients is the 
expression of MLL-AF4 in a subset of bone marrow mes-
enchymal stem cells (MSC) [25]. This was not observed in 
other types of B-ALL and seems to be unique to this group 
of patients. It suggests that the initial translocation occurred 
in a precursor for both the haematopoietic and the stromal 
compartment. To investigate the impact of MLL-AF4 
expression in early development, Bueno et al. induced the 
expression of this fusion gene through a lentiviral vector in 
human embryonic stem cells (hESC) with expression levels 
Table 2  Current clinical trials in B cell acute lymphoblastic leukaemia
Cytogenetic abnormality Risk group Therapeutic target (drug) Clinical trial (as of July 2017)
t(4;11)(q21;q23) MLL-AF4 High I-BET inhibitor (I-BET151 and I-BET762) NCT01943851 (phase I, recruiting)
DOT1L inhibitor (EPZ5676) NCT01684150 (phase I, complete)
NCT02141828 (phase I, complete)
Flavopiridol NCT00278330 (phase I, complete)
Menin–MLL interaction (MI-2, MI-2-2) Preclinical
LEDGF–MLL interaction (CP65 small peptide) Preclinical
WDR5–MLL interaction (MM-401) Preclinical
t(1;19)(q23;p13) E2A-PBX1 Standard mTOR inhibitor (rapamycin or analog) NCT00874562 (phase I, complete)
NCT00081874 (phase I/II, complete)
p110δ inhibitor (idelalisib) NCT01539512 (phase III, complete)
SRC inhibitor (dasatinib) NCT00438854 (phase I, complete)
LCK inhibitor (A-770041) Preclinical
SYK inhibitor (P505-15) Preclinical
AuroraB inhibitor (barasertib-HQPA) NCT00926731 (phase I, complete)
NCT01019161 (phase I, complete)
t(9;22)(q34;q11.2) BCR-ABL1 High PI3K/mTOR inhibitor (PI-103) None (fast in vivo metabolism)
PI3K/mTOR inhibitor (NVP-BEZ235) NCT01756118 (phase I, active)
Farnesyl transferase inhibitor (lonafarnib) NCT00034684 (phase II, complete)
Mutant forms of BCR-ABL (ABL001/asciminib, 
nilotinib)
NCT01528085 (phase II, active)
NCT03106779 (phase III, not yet recruiting)
Native form of BCR-ABL (imatinib) NCT00025415 (phase I, complete)
JAK2 inhibitors (ruxolitinib) NCT01251965 (phase I-II, complete) 
NCT02723994 (phase II, recruiting)
BCR-ABL1-like High Dasatinib (ABL1, ABL2, CSF1R, PDGFRB fusion 
genes)
NCT00438854 (phase II, complete)
Ruxolitinib (EPOR and JAK2 rearrangements) NCT01251965 (phase I/II, complete)
NCT02723994 (phase II, recruiting)
Crizotinib (ETV6-NTRK3) NCT02551718 (ex vivo, recruiting)
Hypodiploidy High PI3K inhibitor (GDC-0941) NCT00876122 (phase I, complete)
PI3K+ mTOR inhibitor (NVP-BEZ235) NCT01756118 (phase I, active)
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similar to those found in patient-derived cell lines [26]. 
MLL-AF4 induced an upregulation of HOX gene expres-
sion and enhanced the formation of haemogenic precursor 
cells  (CD45−CD31+CD34+). This was accompanied by a 
diminished haematopoietic differentiation and an increased 
endothelial cell fate. Therefore, MLL-AF4 does not seem to 
favour haematopoietic commitment during the mesodermal 
to haematopoietic transition; however, MLL-AF4 expression 
in the stromal compartment may increase niche support for 
the cell-of-origin and the leukaemia blasts.
MLL, a regulator of transcription essential 
for embryonic and adult haematopoiesis
MLL, also known as KMT2A, is an H3K4 methyltrans-
ferase that catalyses histone H3 Lys4 methylation through 
its SET domain. This epigenetic mark is associated with 
actively transcribed promoters and open chromatin. MLL 
directly interacts with the nuclear protein Menin (MEN1), 
which is essential for MLL-mediated transcription and for 
MLL-AF4-mediated transformation [27, 28]. Accordingly, 
MEN1 inhibitors were shown to be detrimental to onco-
genic transformation by MLL-fusion genes, independent of 
the MLL partner gene [29, 30]. Inhibitors of WDR5 and 
LEDGF, two partners of MLL, can also disrupt MLL activ-
ity and the oncogenic potential of MLL-AF4 [31–33].
MLL plays a vital role during embryonic development 
by regulating HOX gene expression, which is crucial for 
the specification of segment identity [34]. Mll haploinsuffi-
ciency in mice leads to major disorders in the cervical, lum-
bar and thoracic regions. Hence, Mll is critical for pattern 
formation and proper development of the embryo. A com-
plete knock-out of Mll in mice leads to death at embryonic 
day (E)10.5 because of dysplasia in the branchial arch and 
aberrant segment boundaries of spinal ganglia and somites 
[35]. E10.5 is also the developmental time-point when the 
first definitive haematopoietic stem cells (HSCs) emerge 
in the aorta-gonads-mesonephros (AGM) region in a pro-
cess that depends on Runx1, a transcription factor linked 
to pre-B ALL ([36, 37] and see below). Subsequent work 
from the Korsmeyer group has shown that Mll is important 
for maintaining haematopoietic potential throughout embry-
onic development. Mll is essential for the haematopoietic 
colony-forming potential and proliferation of haematopoietic 
progenitors in the E10.5 yolk sac [38], the tissue in which 
haematopoietic cells are first detected [39]. Mll continues 
to have a role in maintaining the haematopoietic potential 
at later stages in the E12.5 foetal liver and yolk sac [40]. 
Furthermore, Mll-deficient embryonic stem (ES) cells can-
not reconstitute haematopoietic organs in chimeric animals, 
leading to a lack of haematopoietic potential in the foetal 
liver [41]. Importantly, Mll-null AGMs are devoid of HSCs 
[41]. Mll also has a cell-intrinsic role in the self-renewal of 
HSCs from the foetal liver and adult bone marrow since its 
deletion leads to an impaired engraftment in competitive 
transplants [42]. Hence, Mll is a gene that is essential to 
maintain the haematopoietic potential during both embry-
onic and adult development.
AF4, a mediator of RNA elongation essential 
to lymphopoiesis
AF4 is a member of the AF4/FMR2 family that contains 
four members: AFF1/AF4, AFF2/FMR2, AFF3/LAF4 
and AFF4/AF5q31. Most members, with the exception of 
AFF2/FMR2, can translocate with the MLL gene and par-
ticipate in the development of ALL or AML. AF4 is part 
of the AEP complex, which includes other members of 
the AF4/FMR2 family (AF5Q31), the ENL family (ENL 
and AF9) and the p-TEFB elongation factor. The AEP 
complex is important for releasing the paused RNA poly-
merase II, which initiates RNA elongation. As mentioned 
previously, MLL can fuse to more than 80 different part-
ner genes in haematological malignancies, most of which 
are members of the AEP complex. Some members of this 
family (AFF2/FMR2, AFF3/LAF4 and AFF4/AF5q31) also 
localise to nuclear speckles which are structures containing 
pre-mRNA splicing factors [43]. Those structures contain 
the regulatory subunit cyclin T1 and the catalytic domain 
CDK9, which together form the p-TEFB elongation factor. 
P-TEFB can be inactivated by flavopiridol [44], which has 
completed its phase I clinical trial for recurrent B-ALL in 
adults (NCT00278330). Hence, some members of the AF4/
FMR2 family can also participate in the splicing of mes-
senger RNA, and this process could be tightly associated 
with RNA elongation. However, AF4 does not localise to 
nuclear speckles, so it is unlikely that the MLL-AF4 fusion 
gene can deregulate this pathway.
Af4 is ubiquitously expressed, but its level of expression 
is higher in the lymphoid compartment and placenta [45, 46]. 
Af4−/− knockout mice show a severe defect in lymphopoiesis 
compared with Af4+/− mice, as evidenced by reduced num-
bers of B and T cells in the main adult haematopoietic sites 
such as the bone marrow, spleen and thymus [47]. AF4 can 
also promote the expression of CD133, a cell surface marker 
of hematopoietic and cancer stem cells [48]. The immor-
talisation of myeloid progenitors by the MLL-AF4 fusion 
gene requires the AF4-binding platform (pSER domain) as 
shown in colony replating assays [49]. AF4 is also important 
for recruiting selectivity factor 1 (SL1), which is a specific 
pSER domain binder, and this ensures the loading of TBP to 
the TATA box [50]. This study provides new evidence for a 
transactivation role of AF4 in the leukaemogenesis process. 
The N-terminal part of AF4 can bind the pTEFb complex, 
but also recruit TFIIH and MEN1 [51]. This is interesting 
since the AF4-MLL reciprocal fusion gene has also been 
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implicated in B-ALL development. This will be discussed 
later in this section.
The biology of t(4;11) MLL‑AF4 infant leukaemia
Cancer development is a disease that is normally associated 
with the acquisition of an array of mutations throughout a 
lifetime. Paediatric ALL, however, has one of the lowest 
mutation rates, which is estimated at approximately 0.2–0.4 
mutations per MegaBase [52]. Since this disease is usually 
initiated in utero at a developmental stage where the chro-
matin is more open and accessible than in adults [53], it is 
possible that all the factors required by MLL-AF4 to initi-
ate disease are already active. Whole-genome, exome and 
targeted DNA sequencing studies in t(4;11) infant patients 
have confirmed the absence of cooperating mutations in this 
sub-type of leukaemia [54]. A recent study using ultra deep 
sequencing of 36 paediatric t(4;11) MLL-AF4 ALL found 
that 63.9% of them had a mutation in NRAS or KRAS that 
could lead to its hyperactivity [55]; however, experimental 
evidence suggests that these may influence the timing of dis-
ease onset and malignant cell migration, but are not required 
for disease initiation [56, 57], as further discussed below. It 
is thus clear that t(4;11)+ pro-B ALL has a lower mutation 
rate than other subtypes of B cell leukaemia, suggesting that 
MLL-AF4 alone is sufficient to initiate disease.
Several attempts have been made to generate a mouse 
model for MLL-AF4+ leukaemia. First, in 2006, Chen et al. 
developed a constitutive knock-in mouse, in which human 
AF4 was inserted into the mouse Mll locus [58]. They 
obtained some heterozygous Mll-AF4 knock-in animals, 
despite noticeable embryonic lethality. These were smaller 
at birth compared to their wild-type littermates, presented 
with a higher white blood cell count in the peripheral blood, 
increased levels of neutrophils and a bias toward the B lym-
phoid lineage [58]. Cells from Mll-AF4 knock-in mice pro-
duced more pro-B cell colonies in methylcellulose assays 
compared with their wild-type littermates, and could serially 
replate for three rounds. This suggested an increased self-
renewal when Mll-AF4 is expressed and an immortalisation 
of the pro-B cells. However, when those cells were placed 
in liquid culture, they could not survive for more than two 
months, implying that the transformation process was not 
completed. The Mll-AF4 knock-in mice did develop haema-
tological malignancies (lymphoid and myeloid hyperplasia, 
B cell lymphoma and myeloid malignancy) with a median 
time of 570 days. Therefore, MLL-AF4 on its own can lead 
to a haematological malignancy, but this model did not reca-
pitulate the human disease.
Because of the high embryonic lethality rate observed in 
constitutive Mll-AF4 knock-in mice, Metzler et al. developed 
a conditional knock-in model based on the invertor technol-
ogy and the use of specific Cre recombinases [59]. Using 
Cre recombinase expressed under the control of specific 
lymphocyte promoters, they successfully generated mice that 
expressed Mll-AF4 in B lymphocytes (CD19-Cre), T lym-
phocytes (Lck-Cre) or both (Rag-Cre). In all cases, the mice 
developed large diffuse B cell lymphomas with a latency of 
317–475 days, which was shorter than the previous Mll-AF4 
knock-in mice. Even though the phenotype of the disease 
was still dissimilar to the human counterpart, it revealed a 
bias of MLL-AF4-driven disease towards the B lineage even 
when targeted to T cells.
In 2008, Krivtsov et al. published their work with a new 
conditional knock-in mouse model of Mll-AF4, which used 
the Mx1-Cre system to activate the expression of Mll-AF4 
postnatally after an induced interferon response [60]. Fol-
lowing multiple intraperitoneal injections of polyinosinic/
polycytidylic acid (polyI:C) to initiate the expression of Mll-
AF4, 36% of the mice developed a haematological malig-
nancy with a latency of 152 days and a disease phenotype 
that was similar to pre-B ALL, while 27% developed AML. 
It thus appeared that all of these mouse models were miss-
ing a crucial element required for the development of a dis-
ease more representative of the human leukaemia. One of 
the hypotheses was that a human physiological context was 
required. With the emergence of humanized mice that have 
a compromised immune system and can, therefore, tolerate 
human haematopoietic cell transplants (as reviewed in Ref. 
[61]), it is possible to use human haematopoietic cells to 
enhance our understanding of pro-B ALL.
Thus, Montes et al. isolated human cord blood  CD34+ 
haematopoietic stem and progenitor cells and transduced 
them with a lentiviral vector containing the human MLL-AF4 
cDNA [62]. The authors found an increased engraftment of 
human cord blood cells in NSG mice when MLL-AF4 was 
expressed. This was accompanied by an increase in HOXA9 
expression. The clonogenic potential of the cells was slightly 
enhanced in myeloid-forming conditions, but the mice did 
not develop any haematological malignancies. This study 
suggested that human cord blood cells might represent a 
stage of development that is too late to recapitulate the leu-
kaemogenesis happening in patients. In 2016, Lin et al. used 
an alternative approach [63] and created a retroviral con-
struct that contains the human MLL and the mouse Af4 gene 
parts. Compared to the human MLL-AF4 construct, their 
hybrid produced a higher retroviral titer. They transduced the 
lineage negative fraction (Lin-) of mouse adult bone marrow, 
which contains all of the haematopoietic stem and progenitor 
cells, and cultured these in myeloid or lymphoid conditions. 
Following transplantation of the cultured cells, the recipients 
developed AML, irrespective of the culture conditions. This 
may at least partly be due to the Lin− fraction being mostly 
enriched in mature myeloid progenitors such as GMP and 
CMP, which would be preferentially targeted. Interestingly, 
when they transduced human  CD34+ cells derived from cord 
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blood and transplanted these into NSG recipients, the mice 
developed pro-B ALL. The authors propose that the devel-
opment of pro-B ALL requires a human haematopoietic 
context. It does not, however, seem to require a prehaema-
topoietic or hemangioblast precursor, or additional events 
like the reciprocal fusion gene AF4-MLL.
Infant t(4;11) MLL-AF4 pro-B ALL has an in utero origin 
[13]. Therefore, to understand the first stages of the disease, it 
is important to initiate the expression of MLL-AF4 in embry-
onic haematopoietic cells which have unique and different 
properties than adult haematopoietic cells (as reviewed in Ref. 
[64]). Barrett and Malouf et al., therefore, used the condi-
tional Mll-AF4 invertor mice developed by Terry Rabbitts and 
two different Cre lines to target the expression of Mll-AF4 to 
foetal haematopoietic cells: Vav-Cre (definitive haematopoi-
etic cells) and Vec-Cre (haemogenic endothelium) [65]. The 
experimental set-up allowed targeting of all the haematopoi-
etic cells formed during the definitive wave of haematopoiesis, 
but also the haemogenic endothelium that gives rise to HSCs 
in the AGM (E10.5 of development), lymphoid progenitors 
(E9.5) and erythro-myeloid progenitors (E8.5) in the yolk sac 
[66, 67]. The effect of Mll-AF4 on emerging blood cells was 
then analysed throughout haematopoietic development in the 
embryo. Blood cells formed in the AGM and placenta (E11-
E12) showed a slight lymphoid bias in colony assays, but their 
engraftment was similar to control cells, suggesting that the 
transformation process is not initiated at those early stages of 
definitive haematopoiesis. At later stages in the foetal liver 
(E12–E14), when haematopoiesis has established itself, the 
engraftment potential of foetal liver cells was significantly 
enhanced upon Mll-AF4 expression and the B lymphoid bias 
became stronger in colony-forming assays. This was also 
accompanied by a higher production of myeloid colonies. 
Most mice developed B cell lymphomas with a latency of 
437 days (Vec-Cre) or 556 days (Vav-Cre). This study also 
shed light on the cell-of-origin of infant pro-B ALL, which 
will be discussed in the next section.
The lymphoid‑primed multipotent progenitor (LMPP) 
as a potential cell‑of‑origin
Previous studies have suggested that leukaemia originates in 
a haematopoietic progenitor that has a lineage-restricted dif-
ferentiation potential, but has retained stem cell-like features. 
Those stem-cell properties confer higher self-renewal and 
quiescence, which makes them resistant to chemotherapeutic 
agents that can target proliferative leukaemia blasts [68, 69]. 
Over the past few years, studies have shed light on the cell-
of-origin, but the debate is still open, especially for B-ALL.
In one study, Cox et  al. [70] found that the human 
 CD34+CD19− and  CD34+CD10− fractions derived from the 
bone marrow of B cell leukaemia patients aged 1–16 years 
old could engraft immunocompromised NOD/SCID mice 
and lead to the development of a leukaemia with a pheno-
type similar to patients. Long-term cultures of unsorted bone 
marrow became strongly enriched for  CD34+CD19− and 
 CD34+CD10− fractions with time, with a concomitant loss 
of the  CD19+ and  CD10+ fraction, which also correlated 
with their lack of engraftment in xenotransplantation. There-
fore, they concluded that the target cells for leukaemia initia-
tion in B-ALL are immature haematopoietic progenitors that 
have not committed to the B cell lineage.
Le Viseur et  al. sorted leukaemia cells from B-ALL 
patients according to the expression of CD34 and CD19, 
followed by xenotransplantation [71].  CD34+CD19−, 
 CD34+CD19+ and  CD34−CD19+ fractions all engrafted 
robustly and could initiate leukaemia development with a 
phenotype similar to what was observed in patients and a 
mean latency of 11.7 weeks.
A o k i  e t   a l .  r e p o r t e d  t h a t  t h e 
 CD34+CD38−CD19−CD33− bone marrow fraction of infant 
t(4;11) MLL-AF4 pro-B ALL patients contained normal 
haematopoietic stem and progenitor cells since they gave 
rise to normal myelopoiesis and lymphopoiesis in xenotrans-
plantation [72]. The injected cells did not initiate leukaemia 
or expressed MLL-AF4. However, xenotransplantation of 
 CD34+CD38+CD19+ or  CD34−CD19+ cells did lead to leu-
kaemia development, and those cells expressed MLL-AF4. 
The expression of CD19 seems important for the leukaemia 
potential in xenotransplantation, but as mentioned previ-
ously,  CD19− cells derived from patients can engraft and ini-
tiate leukaemia development in other studies [70, 71]. At a 
similar time, Bardini et al. found that the expression of CD34 
and NG2 cannot differentiate leukaemia-initiating cells from 
non leukaemia-initiating cells [73]. They also found some 
Ig/TCR rearrangement in the xenografted cells, suggesting 
that the founder clone could be a haematopoietic progenitor 
that has already undergone some rearrangement  (CD19+). 
There is also a possibility that the founder clone could be a 
cell that has no mature antigen receptor rearrangement (e.g. 
IGH, IGK-Kde, TCRD, TCRG) rearrangement  (CD19−), 
which was observed in leukaemia cells from t(4;11) pro-B 
ALL patients [74]. The question of whether transformation 
begins before the commitment to the lymphoid lineage in 
patients, therefore, requires further investigation.
Using an inducible mouse model in which Mll-AF4 was 
targeted to the first definitive haematopoietic cells during 
development, Barrett and Malouf et al. found an increased B 
lymphoid output in the E12–E14 foetal liver during embry-
onic development compared to the control littermates [65]. 
They isolated two fractions: HSC/MPP  (Lineage−  Sca1+ 
 ckit+  Flt3−  IL7R−; stem cell and immature progenitors) and 
LMPP  (Lineage−  Sca1+  ckit+  Flt3+) and observed a nota-
ble increase in the formation of B cell colonies from both 
populations upon expression of Mll-AF4. These colonies 
were bigger in size compared to colonies formed by control 
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cells and contained mostly pro-B cells (AA4.1−ckit+B220
+CD19+CD43+CD24+IgM−) that could form colonies in 
replating assays. The clonogenic potential of the LMPP was 
around fourfold higher compared to the HSC/MPP fraction. 
All together, these results confirm that leukaemogenesis is 
initiated in utero and that Mll-AF4 confers stem-cell like 
properties to embryonic haematopoietic progenitors. This 
study also suggests that the foetal liver LMPP could be the 
cell-of-origin of t(4;11) MLL-AF4 leukaemia [65].
MLL‑AF4 is a positive regulator of clonogenicity 
and survival
To gain further insights into the role of MLL-AF4 in leukae-
mia, scientists have used various human and mouse cell lines 
to assess its effect on survival, proliferation and clonogenic 
potential. Caslini et al. developed a tetracycline-inducible 
system of MLL-AF4 expression in U937 human monocyte 
cells and observed that an increased expression of MLL-AF4 
leads to an inhibition of proliferation [75]. This phenotype 
was similar to the overexpression of MLL-AF9 [75]. By con-
trast, Thomas et al., using siRNA technology to inhibit the 
expression of MLL-AF4 in SEM and RS4;11 cells, observed 
that the inhibition of MLL-AF4 had a negative effect on the 
clonogenic potential and proliferation of leukaemia cells [76]. 
This was accompanied by a decreased engraftment in SCID 
mice and an upregulation of CD133, suggesting that the cells 
had started to differentiate and were losing their self-renewal 
potential. These seemingly contrasting results suggest that 
either the cell context can impact on the transformation pro-
cess mediated by MLL-AF4 or maintaining the right level of 
MLL-AF4 expression is crucial, with knockdown and over-
expression both having a negative impact on cell prolifera-
tion. The former interpretation is supported by recent work 
from the Mulloy group who revealed an impaired ability of 
MLL-Af4 to transform myeloid cells [77]. This lymphoid 
preference is driven by the Af4 partner and requires a lym-
phoid cellular context. The expression of MLL-AF4 can also 
be modulated by specific microRNAs that can recognize the 
3′UTR of AF4, notably miR-143 [78]. The miR-143 locus is 
highly methylated in MLL-AF4+ leukaemia cell lines, lead-
ing to its downregulation and MLL-AF4 escaping microRNA-
mediated regulation. Restoring the expression of miR-143 in 
MLL-AF4+ leukaemia cells leads to an increase in apoptosis 
and a decrease in cell proliferation. Hence, microRNAs can 
influence leukaemogenesis and bring an additional layer of 
complexity to our understanding of pro-B ALL.
Contributors to t(4;11) MLL‑AF4 leukaemia
All the mice that express MLL-AF4 do develop a haema-
tological malignancy; however, they do not recapitulate 
the human disease that has a fast progression and produces 
leukaemia blasts with a pro-B cell phenotype. These mod-
els suggest that additional events or factors are necessary, 
including changes in gene expression which may not be pre-
sent in the murine context.
FLT3 activity in infant leukaemia
The activity of FLT3 is increased in t(4;11) MLL-AF4 pro-B 
ALL and other cytogenetic groups including t(12;21) ETV6-
RUNX1 and t(9;22) BCR-ABL1 [79]. This can result from 
mutations in the tyrosine kinase domain (TKD) or a tandem 
duplication of the gene, but is usually associated with an 
increased expression of FLT3, commonly as a result of an 
upregulated HOXA9/MEIS1 program [80]. The prognosis 
of t(4;11) MLL-AF4 leukaemia can be predicted with FLT3 
expression. High expression of FLT3 is associated with a 
bad prognosis, a shorter overall survival and a shorter dis-
ease-free survival, while low expression of FLT3 is associ-
ated with a better prognosis. To model the effect of FLT3, 
Montes et al. transduced human  CD34+ cord blood cells 
with MLL-AF4 and either an overactive FLT3 (FLT3-TKD) 
or a wild-type FLT3 [81]. Using xenotransplantation, they 
assessed the development of leukaemia upon activation of 
FLT3. Even though the mice did not develop leukaemia, they 
observed a transient expansion of  CD34+ cord blood cells 
expressing MLL-AF4 upon FLT3 activation.
AF4‑MLL: the reciprocal fusion gene
The reciprocal fusion gene AF4-MLL is present in approxi-
mately 80% of patients diagnosed with t(4;11) MLL-AF4 
leukaemia [82]. Similar to MLL-AF4, it contains cleav-
age sites for Threonine-Aspartase 1 (Taspase 1) which are 
important for its activation and its resistance to proteoso-
mal degradation. AF4-MLL can associate with proteins 
that modulate the activity of RNA polymerase II promot-
ers (e.g. P-TEFB kinase) and alter the histone methylation 
signature by recruiting H3 arginine and lysine methyltrans-
ferases, such as CARM1 and DOT1L, respectively, lead-
ing to an increased H3 methylation signature [83]. There-
fore, both MLL-AF4 and AF4-MLL can increase H3K79, 
H3R2, H3R17 and H3R26 methylation marks. Addition-
ally, AF4-MLL can increase the H3K4 methylation mark 
and extend the activation of gene expression. AF4-MLL can 
also interact with the C-terminal portion of AF4, suggesting 
that MLL-AF4 can be recruited to the same transcriptional 
complex. Neither MLL-AF4 nor AF4-MLL seem to affect 
the efficiency of DNA damage repair [84]. MLL-AF4 and 
AF4-MLL can modulate the transcription of the ALOX5 
gene through the activation of transcription and elongation, 
respectively [85]. The ALOX5 gene encodes the 5-lipoxy-
genase enzyme, which is essential for the formation of pro-
inflammatory leukotrienes. These metabolites of arachidonic 
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acid can activate the immune response and help to establish 
a tumour microenvironment by acting both on cancer cells 
and stromal cells (as reviewed in Ref. [86]). They have also 
been linked to proliferation, as an increased production of 
leukotriene  B4 in B cell chronic lymphocytic leukaemia was 
shown to enhance DNA synthesis [87]. Interestingly, it was 
shown that AF4-MLL can lead to leukaemia, even in the 
absence of MLL-AF4 [88]. Therefore, AF4-MLL appears 
to be important for leukaemia development, but its absence 
in 20% of patients implies it is not always essential.
NRAS and KRAS
The mutation of NRAS and KRAS in t(4;11) MLL-AF4 pro-B 
ALL has been reported in the literature despite the low muta-
tion burden in this subtype of leukaemia [89]. MLL-AF4 can 
also activate the expression of the ELK-1 transcription fac-
tor, which is a downstream effector of KRAS activity [90]. 
This prompted scientists to study its role in leukaemogenesis. 
Crossing a transgenic MLL-AF4 mouse line with a trans-
genic Kras mouse line [57] resulted in the mice developing B 
cell lymphoma or leukaemia characterised by the accumula-
tion of  B220+CD43+CD19+ blasts, splenomegaly and infil-
tration of malignant cells in the lungs. The latency was sig-
nificantly reduced by the presence of Kras mutations. Prieto 
et al. used xenotransplantation to assess the contribution of 
KRAS activation to the transformation of  CD34+ cord blood 
cells expressing MLL-AF4 [56]. They found that the expres-
sion of KRAS favoured the migration of cells to extramed-
ullary organs, but the mice did not develop leukaemia. A 
non-essential role for RAS signalling is also supported by the 
observation made in a recent large-scale sequencing study in 
which activating mutations in the RAS pathway were found 
to be mostly sub-clonal and often lost at relapse [54].
Transcriptional deregulation as a hallmark 
of MLL‑rearranged leukaemia
The expression of MLL-AF4 is associated with an ectopic 
H3K79 methylation profile that is crucial for the transforma-
tion process in infant pro-B leukaemia and requires the aber-
rant recruitment of the DOT1L enzyme [60, 91]. Importantly, 
this is now explored as a potential therapeutic target [91, 92] 
with DOT1L inhibitors being currently tested in clinical tri-
als. In addition, MLL-rearranged leukaemias have the highest 
DNA methylation index among all types of leukaemias [93].
The epigenetic abnormalities result in the upregulation 
in leukaemia blasts of an array of genes which are normally 
expressed in haematopoietic stem cells, such as HOXA9, 
MEIS1, HMGA2 and RUNX1 [37, 94–96]. Interestingly, 
RUNX1 was not only determined to be a direct target of 
MLL-AF4, but the RUNX1 protein was also found to form 
a complex with the reciprocal AF4-MLL fusion protein [97]. 
Around 50% of infant t(4;11) MLL-AF4 patients show an 
upregulation of HOX genes, which in combination with 
MEIS1, participate in the immortalisation process mediated 
by MLL-rearranged genes.
The HMG/high mobility group family of transcription fac-
tors (HMGA1 and HMGA2) are ubiquitously expressed dur-
ing embryonic development, but almost undetectable in adult 
tissues. They are chromatin-remodelling factors that bind AT-
rich regions of the minor groove of DNA. HMGA2 expres-
sion is upregulated in MLL-AF4 leukaemia cell lines which 
leads to an increased cell proliferation that is dependent on 
the hypermethylation of the miR-let-7b promoter [98]. This 
MLL-AF4/let-7b/HMGA2 axis is sensitive to the demethylat-
ing agent 5-azacytidine. Studies have suggested that MLL-
AF4 can modulate the expression of BCL-2 target genes, 
which are members of the intrinsic mitochondrial apoptosis 
pathway [97, 99, 100]. In fact, MLL-AF4 can increase the 
expression of BCL-2 and MCL-1 and repress the transcrip-
tion of BIM through binding of the promoters [28]. Accord-
ingly, the inhibition of MLL-AF4 in the t(4;11)+ SEM cell 
line led to a decrease in H3K79me2/3 methylation at the 
BCL-2 locus and a decrease in H3K27Ac acetylation mark 
at the 3′ end [28, 100]. The expression of BCL-2 resulted 
in resistance to apoptosis, which could be reverted using a 
specific BCL-2-selective inhibitor ABT-199. Inhibition of 
MLL-AF4 also led to reduced binding of the PRC1 protein 
CBX8 to the BIM locus. Similar to the effects of MLL-AF4 
inhibition, treatment of SEM cells with the DOT1L inhibitor 
EPZ5676 caused a loss of the histone marks and a decreased 
expression of BCL-2 and MCL-1, but not BIM.
In 2011, Dawson et al. investigated the effect of an inhibitor 
of the BET family I-BET151 on MLL-rearranged leukaemia 
[101]. I-BET151 works by removing the BRD3/4, PAFc and 
SEC components from chromatin. They found that this inhibi-
tor had a strong effect on the survival of MLL-rearranged 
leukaemia cells derived from patients, and this was partly 
due to the inhibition of transcription of BCL-2, the oncogene 
C-MYC and CDK6, the latter of which is required for the 
exit of haematopoietic stem cells from quiescence [102]. At 
the moment, phase I clinical trials are underway using I-BET 
inhibitors (NCT01943851) [103] and inhibitors of DOT1L 
(NCT01684150, NCT02141828) [104]. The inhibitors for 
menin, LEDGF and WDR5 are still in their preclinical phases 
[105]. The biological features and therapeutic avenues of 
t(4;11) MLL-AF4 pro-B ALL are highlighted in Fig. 1.
The usual suspect: t(12;21) ETV6‑RUNX1
Clinical features of ETV6‑RUNX1+ patients
Approximately 25% of patients diagnosed with paediatric 
pre-B ALL will present with the t(12;21) ETV6-RUNX1 
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translocation, which makes it the most frequent genetic 
insult [106]. The leukaemia blasts from pre-B ALL patients 
are  CD10+, unlike t(4;11)+, and express CD19 and CD34 
[107]. The t(12;21) translocation involves the fusion of two 
transcription factors essential for haematopoiesis: ETV6 and 
RUNX1. Both genes are expressed in HSCs and more mature 
haematopoietic progenitors such as LMPP, CLP, GMP and 
PreMegE [108]. This leads to the formation of a chimeric 
transcription factor that contains the protein–protein inter-
action domain of ETV6 (PNT), located on the N-terminal 
side, with almost the entire RUNX1 gene. The ETV6-
RUNX1 chimeric transcription factor does not contain the 
DNA-binding site of ETV6 (the ETS domain). t(12;21)+ 
patients have a good prognosis and the risk of relapse is 
low compared with t(4;11)+ patients. Nearly all ETV6-
RUNX1+ pre-B ALL patients can be cured with the mini-
mal residual disease/MRD-guided treatment regimen [109]. 
Similar to t(4;11) MLL-AF4, the t(12;21) ETV6-RUNX1 
originates in utero. Studies in twins found that the genomic 
breakpoint of the ETV6-RUNX1 chromosomal transloca-
tion was identical [110], suggesting that the pre-leukaemic 
clone reached the other twin via a shared placenta. How-
ever, only around 1% of newborns that harbour the t(12;21) 
will develop leukaemia [111], suggesting that the develop-
ment of t(12;21) pre-B ALL requires additional mutations. 
It has been reported that RAG-mediated deletions is one of 
the main mutational processes [98]. This leads to chromo-
somal deletions in various genomic loci including ETV6, 
PAX5, BTG1, LIMD1, NR3C2, ATM, AIM1 and BLIMP1 
[112, 113]. A genome-wide association study also identi-
fied TP63 (rs17505102) and PTPRJ (rs920590) as germline 
susceptibility loci in childhood t(12;21) ETV6-RUNX1 
pre-B ALL [114]. Around 15% of t(12;21)+ patients har-
bour an activation mutation in NSD2, which could lead to 
an increase in H3K36 dimethylation [115]. Further studies 
also confirmed that t(12;21) ETV6-RUNX1 pre-B ALL is 
associated with hypermethylation compared to other sub-
types such as t(1;19) E2A-PBX1, which has been associated 
with hypomethylation in the same study [116]. Interestingly, 
ETV6-RUNX1+ patients also show a preserved global H4 
acetylation, which is a favourable prognostic factor [117]. 
A recent study described a group of patients with an ETV6-
RUNX1-like gene expression signature, some of whom also 
harboured deletions in ETV6 and IKZF1 [118]. This paper 
additionally identified a new subset of paediatric pre-B ALL 
patients harbouring a DUX4-rearrangement. This leads to an 
overexpression of DUX4, a homeobox-containing protein, 
and a loss of function of the ERG transcription factor [119].
ETV6 and RUNX1: transcription factors vital 
for embryonic and adult HSCs
In 1997, Wang et al. published the generation of an ETV6 
knock-out mouse line [120], with the complete knock-out 
resulting in embryonic lethality at E10.5 due to an absence 
of angiogenesis in the yolk sac and apoptosis in spe-
cific intra-embryonic cell types. In 2010, Ciau-Uitz et al. 
showed in Xenopus embryos that Etv6 is essential for the 
Fig. 1  Biology of t(4;11) MLL-AF4 pro-B acute lymphoblastic leu-
kaemia. The MLL-AF4 fusion gene and AF4-MLL reciprocal fusion 
gene are shown with their main interaction partners. Both induce a 
deregulated epigenetic signature leading to an upregulation of stem-
cell signature genes, positive regulators of cell division and inhibi-
tors of apoptosis. The DOT1L inhibitor (EPZ5676), I-BET inhibitor 
(I-BET151), p-TEFB inhibitor (flavopiridol), WDR5 inhibitor (MM-
401) and LEDGF inhibitor (CP65 small peptide) are potential thera-
peutic agents that target various members of the MLL-AF4 complex 
and its regulated genes
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specification of HSCs and the arterial identity of the dorsal 
aorta through the regulation of Vegfa expression [121]. This 
study places ETV6 as an essential cell-extrinsic regulator of 
HSC emergence. In adult blood cells, Runx1 is expressed in 
transplantable HSCs, myeloid cells and in some lymphoid 
cells [122], but there is an absolute requirement for the pres-
ence of Runx1 only during the initial generation of HSCs 
during embryogenesis [37]. The lack of Runx1 does not 
affect yolk sac erythropoiesis, but it severely compromises 
definitive haematopoiesis [123].
In 1998, Wang et al. investigated the contribution of 
Etv6−/− embryonic stem cells in mouse chimeras [124]. 
They found that Etv6 is dispensable for foetal liver hae-
matopoiesis, but crucially required for adult bone marrow 
haematopoiesis from the stage of initial bone marrow colo-
nisation. Specifically, they found that Etv6−/− ES cells do 
not contribute to adult myelopoiesis or erythropoiesis, and 
the formation of B cells is also impaired in the absence of 
Etv6. In 2004, Hock et al. modulated the expression of Etv6 
in different blood cell types by crossing mice harbouring a 
conditional (floxed) Etv6 allele with mice expressing CD19-
Cre (B cell), Lck-Cre (T-cell) and Gata1-Cre (erythrocytes 
and megakaryocytes) [125]. They did not observe changes 
in the proportions of B and T cells when Etv6 was excised 
specifically in B or T cells, but found a significant reduc-
tion in the frequency of megakaryocytes. Using Mx1-Cre, 
however, led to a total disruption of adult HSC activity, 
suggesting that Etv6 is essential for HSC survival, while 
haematopoietic progenitors further downstream are largely 
Etv6-independent [125].
In 2015, Rasighaemi et al. inhibited the expression of 
Etv6 during zebrafish development using two distinct mor-
pholinos [126]. The authors noted changes in primitive and 
definitive haematopoiesis during embryonic development, 
notably a decrease in erythrocytes and myeloid cells along-
side an increase in lymphopoiesis. Together, those studies 
highlight the essential role for ETV6 in both the emergence 
of HSCs during embryonic development (cell-extrinsically) 
and their maintenance in adult tissues (cell-intrinsically). In 
addition, they show that Etv6, at least in zebrafish, can affect 
lymphopoiesis, which is interesting given that the complete 
inactivation of ETV6 is a frequent genetic event in t(12;21)+ 
pre-B ALL.
The biology of t(12;21) ETV6‑RUNX1 pre‑B ALL
The ETV6-RUNX1 fusion gene possesses the PNT domain 
of ETV6, which is a transcriptional repressor of the Ets 
family. The PNT domain is the protein interaction domain 
and recruits proteins like NCOR, SIN3A and histone dea-
cetylases to inhibit transcription [127]. The use of HDAC 
inhibitors confirmed that the recruitment of histone deacety-
lases by the PNT domain was part of the leukaemogenesis 
process, and this treatment led to an accumulation of cells 
in the G0/G1 phase [128]. Importantly, it affects RUNX1 
target genes. For example, ETV6-RUNX1 can inhibit the 
transcriptional activation of MCSFR, normally promoted by 
RUNX1 or repressed by ETV6, and this inhibition requires 
the RUNX1 and C/EBPa consensus sequences [129]. ETV6-
RUNX1 was also shown to have a dominant-negative effect 
on ETV6-mediated transcription, with increasing amounts 
of ETV6-RUNX1 inhibiting the ETV6-mediated transcrip-
tional repression of stromelysin-1 [130]. Other transcrip-
tional targets of ETV6 include SPHK1, PTGER4 and CLIC5, 
which can promote survival and proliferation of leukaemia 
cell lines [131, 132]. Interestingly, ETV6-RUNX1 can also 
activate the expression of RAC1, which phosphorylates 
and activates STAT3, leading to a constitutive activation of 
C-MYC [133]. Accordingly, the inhibition of STAT3 activ-
ity through specific inhibitors induced cell death in the pre-
leukaemia cell, and shRNA directed against Stat3 led to a 
longer latency in pre-B ALL development.
Similar to t(4;11) MLL-AF4, many mouse models have 
been developed to assess the role of ETV6-RUNX1 in dis-
ease development. In 2001, Andreasson et al. published a 
transgenic mouse model, in which the human ETV6-RUNX1 
fusion gene was inserted into the locus of the immunoglobu-
lin heavy chain enhancer/promoter  EµVHP [134]. This pro-
moter is active in pre-B cells, so the expression of ETV6-
RUNX1 was initiated in the population of leukaemia blast 
cells observed in patients. The mice did not display any signs 
of haematological malignancy even though the expression of 
ETV6-RUNX1 was detected in the bone marrow and spleen. 
This is the first study to suggest that ETV6-RUNX1 alone is 
not sufficient to drive the development of pre-B ALL.
Bernardin et al. used a transduction approach to study 
the role of ETV6-RUNX1 in wild-type and  Cdkn2a−/− bone 
marrow cells, followed by transplantation [135]. The alpha 
form of Cdkn2a  (p16INK4a) binds to cyclin-dependent kinase 
Cdk4 and Cdk6 to inhibit their kinase activity [136]. This 
leads to a lack of phosphorylation of pRB and a G1 arrest. 
The beta form of Cdkn2a  (p19ARF) activates the p53-MDM2 
pathway leading to a G1 cell cycle arrest in both G1 and 
G2/M [137]. Bernardin et al. found that mice developed an 
acute leukaemia with a similar penetrance in transduced 
wild-type and  Cdkn2a−/− cells, but the latency was shorter 
when Cdkn2a was deleted. Li et al. crossed a Tie2-Cre with 
an inducible ETV6-RUNX1 transgenic mouse, thus tar-
geting expression to endothelial and haematopoietic cells. 
These mice were then bred to a Cdkn2a-null mouse to assess 
the contribution of Cdkn2a to leukaemogenesis. Mice that 
expressed ETV6-RUNX1 and lacked Cdkn2a developed 
pre-B ALL with a high frequency, and the latency was fur-
ther reduced with irradiation [138]. Considering that Cdkn2a 
expression is lost in about 25% of t(12;21)+ pre-B ALL 
patients, both studies suggest that the inactivation of Cdkn2a 
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is an event that contributes to accelerate leukaemia develop-
ment [139].
Tsuzuki et al. used a similar approach to Bernardin et al. 
and transplanted bone marrow cells transduced with a ret-
rovirus expressing ETV6-RUNX1 to investigate the first 
stages of disease development [140]. They found that ETV6-
RUNX1 increased ckit+ haematopoietic stem and progenitor 
cells, but also increased the proportion of pre-pro-B and 
pro-B cells in the bone marrow. This B cell differentiation 
arrest was not complete since there were still pre-B and 
mature B cells being formed from ETV6-RUNX1+ bone 
marrow cells. The myeloid and erythroid compartments 
were largely unaffected. This study suggests that ETV6-
RUNX1 can contribute to a differentiation arrest during B 
lymphoid development, but its presence alone is not suf-
ficient for a complete arrest.
Similarly, Fischer et al. transduced early haematopoietic 
progenitors with ETV6-RUNX1 and investigated the B cell 
differentiation arrest and the incidence of leukaemia devel-
opment in their cohort [141]. Even though their mice did not 
get sick, the ETV6-RUNX1 transduced cells formed more 
pre-B cells. When ETV6-RUNX1 expression was higher, 
the transduced cells started to express ckit and the CD11b 
myeloid marker. It is plausible that the fine-tuning of ETV6-
RUNX1 expression is crucial for restricting the differen-
tiation program towards the B lineage fate. This phenotype 
has lately been attributed to the transactivation domain of 
ETV6-RUNX1, which is part of the RUNX1 part of the 
fusion gene [142].
Similar to t(4;11) MLL-AF4 pro-B ALL, xenotransplan-
tation has been used to assess the role of ETV6-RUNX1 in 
a human cellular context [143]. The  CD34+CD38−CD19+ 
fraction of t(12;21) ETV6-RUNX1+ patient pre-B ALL 
bone marrow was transplanted into severe combined immu-
nodeficient mice (NOD/SCID). This population was able to 
engraft and form B cell colonies that could serially replate. 
They were also resistant to apoptotic stimuli induced by 
camptothecin, Fas-L and melphalan.
Schindler et al. used a different approach and inserted 
the human RUNX1 gene into the mouse Etv6 locus to gener-
ate a fusion gene that, like in patients, is under the control 
of endogenous Etv6 gene regulatory elements [144]. The 
expression of the Etv6-RUNX1 gene was activated with 
Gata1-Cre to target early haematopoiesis in the embryo. 
About two-thirds of the embryos survived an early lethality 
and showed no obvious phenotype apart from a mild B cell 
expansion even though foetal liver cells failed to reconstitute 
the lymphoid compartment upon transplantation. A failure 
of Etv6-RUNX1-expressing HSCs to differentiate down the 
lymphoid lineage was further confirmed using Mx1-Cre and 
Vav-Cre induction.
Kantner et al. created a mouse model of ETV6-RUNX1 
by knocking the human ETV6-RUNX1 into the CD19 locus 
[145]. This led to the expression of ETV6-RUNX1 under 
the control of the CD19 promoter, which will target com-
mitted B lymphoid cells exclusively. The expression level 
of ETV6-RUNX1 was similar to ETV6, suggesting that it 
recapitulates the expression level found in leukaemia blasts 
from patients. The transgenic mice showed similar propor-
tions of the Hardy B cell fractions along the differentiation 
pathway in the bone marrow and a slight, but not significant, 
increase of immature B cells in the spleen. Even though the 
mice did not get sick, pro-B cells showed an elevated cellular 
level of reactive oxygen species, which translated into an 
accumulation of DNA damage. This study unravelled a new 
function of the ETV6-RUNX1 gene as a mediator of DNA 
damage, a step necessary for disease progression.
Another transduction approach targeted immature (Lin-
eage− or ckit+) cells or pro-B cells from the foetal liver 
to study the early changes conferred by the ETV6-RUNX1 
fusion gene in leukaemogenesis [146]. One retroviral vec-
tor conferred high expression of ETV6-RUNX1 while the 
other vector conferred lower expression, similar to what is 
observed in patients. The cells with the lower expression 
of ETV6-RUNX1 could form more and bigger B lymphoid 
colonies, whereas high expression of ETV6-RUNX1 had a 
negative impact on B cell development. The ETV6-RUNX1 
low-expressing cells also showed an enhanced replating 
potential, demonstrating that low expression of ETV6-
RUNX1 conferred self-renewal to pro-B cells. Interest-
ingly, this phenotype was specific to foetal cells and was 
not recapitulated in adult cells. Therefore, similar to what is 
reported for MLL-AF4, it is crucial to maintain an expres-
sion level similar to what is observed in patients and to ini-
tiate the expression of the fusion gene at the right stage of 
development.
Several studies investigated the involvement of additional 
mutations in t(12;21) ETV6-RUNX1 leukaemogenesis. The 
ASEF gene, a RAC specific guanine nucleotide exchange 
factor, was reported to be overexpressed in t(12;21) ETV6-
RUNX1 pre-B ALL, but not in other haematological malig-
nancies [147]. Its overexpression led to increased B cell 
potential both in vitro and in vivo, but was not sufficient 
to induce pre-B ALL (not even in the presence of ETV6-
RUNX1). To study t(12;21) in the context of accumulating 
mutations, van der Weyden et al. generated a mouse model 
that expressed the Etv6-RUNX1 fusion gene and the Sleep-
ing Beauty transpose under the control of the Etv6 promoter 
[148]. Around 20% of the mice developed pre-B ALL with 
a latency of approximately 1 year, which compared to the 
models mentioned previously and which can be attributed 
to the presence of additional mutations. By sequencing the 
genomic DNA from sick mice, they found mutations in genes 
that correlated with patient data, one of which was Ikzf1 
(Ikaros). The deletion of Ikzf1 has been reported in pre-B 
ALL and leads to an increased expression of HSC genes 
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and reduced expression of B cell genes [149]. It is essential 
for pre-B cell differentiation [150], so its inactivation would 
favour the differentiation arrest observed in pre-B ALL. The 
same group then replaced the Sleeping Beauty transposase 
component with a Pax5 haploinsufficiency [151]. PAX5 is 
often deleted or mutated in t(12;21) ETV6-RUNX1 pre-B 
ALL, with the mutations leading to decreased transcriptional 
activity [152]. Mice developed a transplantable B cell ALL 
that was similar to their previous model [148]. Both studies 
confirmed that t(12;21) ETV6-RUNX1 pre-B ALL requires 
additional mutations to progress to a full-blown leukaemia. 
Interestingly, Martìn-Lorenzo et al. also showed that the 
haploinsufficiency of Pax5 alone can lead to the develop-
ment of pre-B ALL when the immunological system of 
the mouse is challenged by an environment that contains 
pathogens [153]. Both the study by van der Weyden et al. 
and the one by Martìn-Lorenzo et al. suggested that somatic 
mutations in Jak3 could also facilitate leukaemia progression 
[151, 153]. One of the main oncogenic drivers in t(12;21) 
ETV6-RUNX1 pre-B ALL is RAG-mediated recombina-
tion [154]. In 2015, Swaminathan and Klemm et al. showed 
that genetic lesions in ETV6-RUNX1+ pre-B ALL are usu-
ally mediated by AID or RAG1 [155]. Their activity is also 
increased through chronic inflammation, highlighting the 
contribution of an overstimulation of the immune system 
to leukaemogenesis. Another study measured a ten-fold 
elevation of RAG1 in ETV6-RUNX1+ patients compared to 
other subtypes of pre-B ALL and found that AID was more 
expressed in patients lacking a cytogenetic change [156]. 
All these studies combined suggest that the expression of 
ETV6-RUNX1 leads to an arrest in the B cell differentia-
tion, but the complete arrest and proliferation of leukaemia 
blasts requires additional genetic events such as the loss of 
Pax5 or Cdkn2a activity, which are potentially mediated by 
an elevated RAG-mediated recombination. The biological 
features of t(12;21) ETV6-RUNX1 pre-B ALL are summa-
rised in Fig. 2.
The other usual suspect: t(1;19)(q23;p13) 
E2A‑PBX1
Clinical features of E2A‑PBX1+ pre‑B ALL
The t(1;19) E2A-PBX1 translocation occurs in approxi-
mately 25% of paediatric pre-B ALL. It leads to the fusion 
of PBX1 exons containing the DNA-binding domain and 
the homeobox domain with the exons of E2A contain-
ing the transactivation domain [157]. Alternative splicing 
leads to the expression of five E2A-PBX1 proteins, where 
 p85E2A-PBX1 and  p77E2A-PBX1 are the dominant isoforms 
[158]. The transforming activity of both proteins is poor 
in vitro, but can lead to tumour formation in nude mice. 
Similar to other pre-B ALL, the leukaemia blast popula-
tion in patients is  CD10+CD19+CD34+ [94]. This subtype 
of leukaemia has been associated with a poor prognosis, 
but this is mostly for patients that have a balanced t(1;19) 
translocation [159].
Fig. 2  t(12;21) ETV6-RUNX1 leukaemia pre-B acute lymphoblas-
tic leukaemia. The different parts of the ETV6-RUNX1 fusion gene 
are depicted and include the repression domains of ETV6 with almost 
the entire RUNX1 gene. The ETV6-RUNX1 fusion gene can alter 
gene expression by targeting RUNX1- and ETV6-target genes such 
as MCSFR and stromelysin-1. This leukaemia requires cooperat-
ing genetic mutations including the inactivation of ETV6, IKAROS, 
PAX5, CDKN2A and overexpression of ASEF. The prognosis is excel-
lent and almost all patients are cured under the current therapy regi-
mens
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E2A is crucial for the maturation of B lymphoid cells
The E2A locus, also known as TCF3, expresses two proteins: 
E12 and E47. Once these helix-loop-helix proteins dimerise, 
they bind E-box sites in promoters and enhancers of genomic 
DNA to regulate gene expression [160]. E2A is an important 
regulator of B cell development. The knock-out of E2a in 
mice results in a high rate of post-natal death [161, 162]. The 
surviving embryos suffered from growth retardation and an 
absence of B lymphoid cells, due to reduced levels of Pax5 
in the foetal liver. The remaining lineages (T cells, erythro-
cytes, granulocytes and macrophages) were unaffected by 
the knock-out of E2a. The expression of E2a peaks dur-
ing the pro-B to pre-B cell transition once Scl is turned off, 
and is subsequently downregulated once IgM expression is 
turned on [163].
E2A activity is negatively regulated by serum growth 
factors and cell cycle entry, as well as by the ID proteins. 
The family of ID proteins has been implicated in cancer 
development and can inhibit the transcriptional activity of 
Ets transcription factors as well as members of the paired 
domain transcription factors such as Pax5 (as reviewed in 
Ref. [164]). The expression of ID2 and ID3 is significantly 
reduced in pre-B ALL compared to AML, suggesting that 
their presence is not favourable to pre-B leukaemia blasts 
[165]. Interestingly, the activity of E2a is also reduced in 
the bone marrow and spleen of aging mice [166], at a time 
when HSCs show a trend towards producing fewer lymphoid 
cells [167]. Overall, the modulation of E2A activity can lead 
to perturbation in B cell development, thus explaining its 
involvement in paediatric pre-B ALL.
PBX1, a member of the Hox family of genes
PBX1 is a TALE-class homeodomain transcription fac-
tor that interacts with other members of the HOX family 
of genes to increase their DNA-binding specificities and 
affinities [168]. PBX1 is a DNA-binding partner of MEIS1 
[169], which is also upregulated in t(4;11)+ MLL-AF4 
pro-B ALL. The knock-out of Pbx1 in mouse embryonic 
development leads to profound anaemia and death by E16 
because of severe skeletal defects [170]. The absence of 
Pbx1 also results in abnormalities in the patterning of the 
great arteries and cardiac outflow tract during embryonic 
development [171].
In embryonic haematopoiesis, Pbx1 deficiency causes a 
decrease in myeloid colony-formation and a severe reduc-
tion in the engraftment of HSCs from the foetal liver [170]. 
Pbx1 is highly expressed on the ventral site of the E11.5 
AGM, especially in the mesenchyme, but also in haema-
topoietic progenitors and individual endothelial cells. It 
continues to be expressed in foetal liver haematopoietic 
progenitors at later stages and is vital for maintaining 
definitive haematopoiesis. Pbx1 also plays an essential role 
in maintaining the quiescence of long-term adult HSCs and 
in lymphopoiesis [172, 173]. Therefore, the disruption of 
Pbx1 activity can compromise self-renewal and lymphoid 
potential of haematopoietic stem and progenitor cells.
The biology of t(1;19) E2A‑PBX1 pre‑B ALL
The E2A-PBX1 fusion gene is a chimeric transcription fac-
tor that lost its ability to interact with MEIS1, but can still 
interact with HOX genes [174]. Whereas PBX1 transcrip-
tional activity is normally low, E2A-PBX1 can constitutively 
activate the transcription of PBX1 targets [175]. The sta-
bility of the E2A-PBX1 fusion gene can be decreased by 
HDM2, which promotes ubiquitination and degradation, and 
increased through acetylation by GCN5 [176]. The interac-
tion between E2A-PBX1 and GCN5 facilitates the expres-
sion of target genes such as WNT16 [177], a secreted signal-
ling protein that can activate the expression of Notch ligands 
(DIc and DId) required for definitive haematopoiesis [178]. 
Similar to other B cell leukaemias, several mouse models 
have been developed to understand the role of E2A-PBX1 
in leukaemogenesis.
In their 1993 manuscript, Kamps et al. transduced haema-
topoietic progenitors from the bone marrow with a retrovirus 
encoding  p85E2A-Pbx1, one of the major isoforms, and trans-
planted these cells to assess leukaemia development [179]. 
The mice developed leukaemia 11–30 weeks post-transplan-
tation and presented with splenomegaly and an infiltration 
of the liver and lungs with proliferating blasts. These blasts 
did not express markers of B or T-cells, but expressed mye-
loid markers, suggesting that the mice had developed AML, 
most of which could also grow as granulocytic sarcomas. 
Using a similar experimental scheme, Sykes et al. found that 
early pro-T cells immortalised by E2A-PBX1 can generate 
a myeloid leukaemia (AML) when injected into mice [180]. 
They also suggested a co-dependence between Scf and E2A-
PBX1 for pro-T cell proliferation, which is similar to the 
co-dependence of SCF and MEIS1 in AML.
In 1993, Uckun et  al. presented the results from 
xenotransplantations of human t(1;19) pre-B ALL leu-
kaemia blasts into SCID mice [181]. The mice developed 
pre-B ALL within 7–12 weeks after transplantation, with 
a phenotype recapitulating the human disease. Interest-
ingly, the engraftment was higher when the pre-B ALL 
blasts came from a patient that relapsed, whereas the pre-B 
ALL blasts from patients with no relapse did not engraft 
as well. This study highlights the relationship between the 
prognosis in patients and the engraftment ability of leu-
kaemia blasts, suggesting the re-acquisition of stem-cell 
like features in poor prognosis pre-B ALL.
Dedera et al. generated a transgenic mouse model of 
t(1;19) E2A-PBX1 in which the expression of the fusion 
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gene is under the control of the immunoglobulin heavy 
chain (IgH) variable region promoter fused to the IgH 
enhancer (Eµ) [182]. This targets the expression of E2A-
PBX1 exclusively to lymphoid cells. Transgenic mice 
developed T cell leukaemia or lymphoma by 5 months of 
age. Before the onset of disease, a reduction in the number 
of thymocytes and bone marrow B lymphoid progenitors 
was observed. The remaining thymocytes were larger in 
size compared with cells from control animals, suggest-
ing higher replication and proliferation, but they also 
exhibited a higher rate of cell death. This suggested that 
E2A-PBX1 can induce both proliferation and apoptosis 
simultaneously.
Through the inactivation of CD3 expression, Bijl et al. 
developed a mouse model which lacked immature and 
mature T cells [183]. E2A-PBX1/CD3ε−/− mice developed 
a pre-B cell leukaemia with a latency of around 400 days 
that was accompanied by an activation of the Hox locus. 
This feature is also observed in t(4;11) MLL-AF4 pro-B 
ALL, and thus suggests that HOX activation is involved in 
another subtype of pre-B ALL.
Using the same mouse model, Hassawi et al. then inves-
tigated the role of Hoxa9 in t(1;19) E2A-PBX1 pre-B ALL 
[183, 184]. The overexpression of Hoxa9 promoted B cell 
proliferation and led to faster disease progression in E2A-
PBX1/CD3ε−/− mice. This was accompanied by reduced 
levels of Pax5 and Ebf1 gene expression, and an activation 
of Flt3. The same group also tested the role of HOXB4 in 
t(1;19) E2A-PBX1 pre-B ALL [185]. First, they performed 
retroviral transduction of  B220+ cells derived from the bone 
marrow of E2A-PBX1/CD3ε−/− mice and found that the 
expression of the HOXB4 gene led to an increased produc-
tion of pro-B cells in vitro, a phenotype linked to prolif-
eration. These cells also exhibited a higher colony-forming 
potential compared with control cells. Second, they gener-
ated a HOXB4/E2A-PBX1/CD3ε−/− mouse line in which 
HOXB4 and E2A-PBX1 were co-expressed in lymphoid 
cells. The latency of the disease was not significantly differ-
ent between E2A-PBX1/CD3ε−/− and HOXB4/E2A-PBX1/
CD3ε−/− mice, but the authors detected a higher number of 
leukaemia-initiating cells upon HOXB4 expression. These 
studies suggest that HOXA9 and HOXB4 can participate 
in B cell leukaemogenesis through different mechanisms.
In a recent xenotransplantation study with the 697 leu-
kaemia cell line derived from a t(1;19)+ pre-B ALL patient 
[186], the aim was to investigate the role of autophagy in 
leukaemia development through rapamycin treatment which 
inhibits mTOR activity, since it is known that the activa-
tion of autophagy can downregulate E2A-PBX1 expression 
[187]. All mice developed pre-B ALL with splenomegaly 
and hepatomegaly, regardless of the rapamycin treatment. 
However, the mice that received a rapamycin inhibitor after 
transplantation (or received cells that had been treated with 
a rapamycin inhibitor before transplantation) had a longer 
survival period and showed decreased infiltration of leukae-
mia blasts in the liver. Therefore, the inhibition of the PI3K/
AKT/mTOR pathway may assist in eradicating leukaemia 
blasts, and there is ongoing work aimed at developing an 
inhibitor that will be useful in the clinic (as reviewed in 
Ref. [188]).
In a more recent mouse model, Duque-Afonso et al. used 
a conditional E2A-PBX1 transgenic mouse line in combina-
tion with CD19 or Mb1-driven Cre recombinase to target 
B cells [189]. They also employed Mx1-Cre to induce the 
expression by polyI:C injection. All mice developed pre-B 
ALL characterised by a higher white blood cell count, 
reduced platelet and red blood cell counts in the peripheral 
blood and splenomegaly. B cell maturation was found to be 
blocked at the pro-B to early pre-B transition. One of the 
most recurrent secondary mutations in those mice affected 
the activation of the Jak/Stat pathway, which may represent 
another interesting therapeutic avenue. Similar to t(12;21) 
ETV6-RUNX1 pre-B ALL, Pax5 haploinsufficiency also 
accelerated leukaemia onset.
Subsequently, the same group reported hyperphospho-
rylation of Plcγ2 in E2A-PBX1+ mouse leukaemia blasts 
from the same model [190]. Plcγ2 is a key enzyme in B cell 
receptor signalling [191]. This hyperphosphorylation was 
associated with an increase in proliferation and was medi-
ated by Zap70 (zeta chain associated protein kinase), Lck 
(lymphocyte-specific tyrosine kinase from the SRC family) 
and Syk (spleen tyrosine kinase), which are downstream tar-
gets of the E2A-PBX1 fusion gene. SYK can also upregulate 
BCL6, a gene essential for the formation of polyclonal B 
cells and involved in pre-B cell self-renewal [192]. Leukae-
mia blasts (pre-BCR+ ALL) can thus hijack the pre-BCR 
signalling pathway to induce differentiation arrest and avoid 
clonal extinction, and reactivating this pathway may be an 
attractive therapeutic target (as reviewed in Ref. [193]). 
Therefore, they also assessed the clonogenic potential of 
pre-BCR+ and pre-BCR− mouse leukaemia cells in the 
presence of an LCK inhibitor (A-770041) or SYK inhibitor 
(P505-15). Encouragingly, both inhibitors led to a significant 
decrease in colony-forming activity in vitro and increased 
the survival in vivo, with pre-BCR+ leukaemia cells being 
more sensitive to A-770041 and P505-15 compared with 
pre-BCR− leukaemia cells. Pre-BCR+ leukaemia blasts 
are further characterised by a constitutive activation of the 
PI3K-AKT signalling pathway and SRC kinase, as well as a 
downregulation of STAT5 activity [194]. The activation of 
pre-BCR is more frequent in patients with PBX1 rearrange-
ment and is rarely seen in patients with a MLL rearrange-
ment, t(12;21) ETV6-RUNX1 or t(9;22) BCR-ABL1.
Very recently, Eldfors et al. reported promising results 
with idelalisib, a phosphatidylinositol 3-kinase delta (p110δ) 
inhibitor, in a drug-sensitivity assay with leukaemia blasts 
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from a t(1;19)+ relapse patient [195]. The viability of the 
leukaemia cells was greatly reduced compared with cells 
from a healthy donor. It also seemed to be more specific 
to the E2A-PBX1 fusion gene since leukaemia cell lines 
harbouring other genetic rearrangements were not as sensi-
tive to idelalisib. P110δ is important for maintaining PI3K 
activity in mature B cells [196], and since the expression of 
p110δ seems to be more specific to haematopoietic cells, 
idelalisib may have minimal off-target effects.
Aurora B kinases are overexpressed in many types of 
paediatric pre-B ALL, but their expression is even higher in 
t(1;19) E2A-PBX1+ patients [197]. Interestingly, leukaemia 
cell lines show a significant decrease in proliferation when 
the expression of Aurora B kinase is downregulated through 
shRNAs or LNA-oligos. In addition, primary leukaemia 
cells from patients are more sensitive to the inhibitor bara-
sertib-HQPA when Aurora B kinases are highly expressed. 
This is due to an increase in histone 3 phosphorylation at 
Serine 10, which is heavily phosphorylated during meta-
phase (as reviewed in Ref. [198]), and results in an accumu-
lation of cells in the G2/M phase of the cell cycle, unable to 
complete cell division.
Rapamycin and its analogues are showing promising 
results in phase I and phase I/II clinical trials (NCT00874562 
and NCT00081874), and a phase III clinical trial is com-
pleted for relapsed chronic lymphocytic leukaemia patients 
and shows that idelalisib improved their overall survival 
[199] (see also NCT01539512). This drug could also ben-
efit B-ALL patients [195]. The LCK and SYK inhibitors 
are still in their preclinical phase. Phase I clinical trial for 
dasatinib (NCT00438854) and barasertib (NCT00926731, 
NCT01019161) are also completed. The biological features 
and therapeutic avenues of t(1;19) E2A-PBX1 pre-B ALL 
are highlighted in Fig. 3.
The famous one: t(9;22) BCR‑ABL1/Philadelphia 
chromosome
Clinical features of t(9;22)+ leukaemia
The Philadelphia (Ph) chromosome is found in about 1–3% 
of paediatric pre-B ALL, and around 25% of adult patients 
[200]. BCR-ABL1 (or BCR-ABL) is also the main driver 
of chronic myelogenous leukaemia (CML) with a risk of 
blast-crisis [201, 202]. This chromosomal translocation 
leads to the fusion of the 5′ region of the BCR gene with the 
sequences upstream of the second exon of the ABL1 gene 
(almost the entire gene coding for this tyrosine kinase), giv-
ing rise to the p190 fusion protein found in approximately 
85% of Ph+ paediatric ALL and 50–70% of Ph+ adult 
ALL [203, 204]. In adult CML, the fusion gene contains a 
larger portion of BCR, resulting in a 210 kDa fusion protein 
(p210). P210 can also be found in 15% of paediatric ALL 
and 30–50% of adult ALL [204]. Both p190 and p210 have 
constitutive kinase activity that can activate many pathways 
including RAS, RAC, PI3K/AKT/mTOR, NF-κB and JAK/
STAT (as reviewed in Ref. [205]) [206]. P230 can be found 
Fig. 3  t(1;19) E2A-PBX1 pre-B acute lymphoblastic leukaemia. 
E2A-PBX1 can interact with GCN5 to increase its stability through 
acetylation or with HDM2 to initiate its degradation through ubiq-
uitination. E2A-PBX1 can constitutively activate the expression of 
PBX1- target genes, which are expressed at low levels under physi-
ological conditions. Many biological pathways contribute to t(1;19)+ 
pre-B ALL including the activation of Notch ligands, mTOR/PI3K/
AKT, JAK/STAT, AuroraB kinase and the hyperphosphorylation of 
PLCγ2 through specific kinases. Potential therapeutic agents that tar-
get these pathways are shown in red 
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in rare cases of CML and has a lower intrinsic kinase activ-
ity compared to p190 and p210 [204, 207]. Patients with 
CML are treated with the ABL1 kinase inhibitor imatinib 
mesylate, which ensures stable remission. Even though 
patients with pre-B ALL are less sensitive to tyrosine kinase 
inhibitors [208], the combination with standard chemother-
apy has greatly increased the disease-free survival in both 
adults [209–211] and children [212, 213]. For example, the 
addition of imatinib increased the 4-year disease-free sur-
vival from 59% to 75% in paediatric ALL [214] (see also 
clinical trial NCT00025415). Recently, it was suggested that 
the ABL1 kinase inhibitor asciminib (ABL001), in combi-
nation with nilotinib, could eradicate the development of 
chronic myelogenous leukaemia in xenografts [215]. Both 
inhibitors can target the BCR-ABL1 mutant forms that 
are resistant to imatinib [216]. ABL001 is currently under 
clinical trial for t(9;22)+ ALL (NCT03106779). Similar to 
t(12;21) ETV6-RUNX1 pre-B ALL, a genome-wide associa-
tion identified a GATA3 susceptibility locus (rs3824662) that 
increases the risk of ALL [217]. This locus is overrepre-
sented in all patients, but even more in Ph+ ALL adolescents 
and young adults and relapsed patients [217, 218]. The dele-
tion of IKAROS is another frequent genetic event in t(9;22) 
BCR-ABL1 pre-B ALL [219]. A recent study by Witkowski 
et al. suggested that Ikaros has a tumour suppressor activity 
in Ph+ murine B-ALL and its inactivation is crucial for the 
maintenance of leukaemia [220].
BCR: a breakpoint cluster region protein with kinase 
activity
BCR has an intrinsic serine/threonine kinase activity that is 
responsible for phosphorylating BCR serine and threonine 
residues [221, 222]. The BCR protein can also be phospho-
rylated by BCR-ABL1 in the part derived from the first exon 
[154]. The phosphorylation of Tyrosine 177 of BCR by FPS/
FES protein tyrosine kinases leads to the binding of Grb2, 
an activator of Ras [223]. This interaction is important for 
p190 BCR-ABL1 leukaemogenesis through GAB2-SHP2 
signalling [224]. The phosphorylation of Tyrosine 360 is 
important for the Bcr-mediated transphosphorylation of 
casein and histone H1, but also for inhibiting the serine/
threonine kinase activity [225].
ABL1: a non‑receptor tyrosine kinase involved in B cell 
development
ABL1 is a member of the c-ABL kinase family and can be 
found in the cytoplasm as well as in the nucleus where it 
displays DNA-binding activity. The ablation of the C-ter-
minal part of Abl in mice leads to a reduction in the B 
cell compartment, especially at the pro-B and pre-B stage 
[226]. The inhibition of c-ABL through a specific antisense 
oligonucleotide in  CD34+ human bone marrow cells leads 
to an accumulation of cells in the G0/G1 phase of the cell 
cycle and a decrease in proliferation [227]. It also causes a 
significant loss in the formation of granulocyte-macrophage 
colonies. Abl was shown to activate JAK2 phosphoryla-
tion in haematopoietic cells [228], a pathway involved in 
many haematological malignancies. Similar to other genes 
involved in leukaemia, ABL1 is involved in haematopoiesis 
and B-lymphoid development.
Biology of t(9;22) BCR‑ABL1 pre‑B ALL
In 1990, Heisterkamp et al. published a mouse model in 
which they used the metallothionein-1 promoter, which is 
active in most tissues, to express BCR-ABL1 [229, 230]. 
60% of their transgenic mice developed an acute lympho-
blastic leukaemia similar to paediatric pre-B ALL, while 
20% developed a myeloid leukaemia which resembled the 
blast crisis phase of chronic myelogenous leukaemia. There 
was no thymus involvement for most animals, and the dis-
ease progressed rapidly within 10–58 days after birth. Inter-
estingly, expression of BCR-ABL1 under the control of the 
BCR promoter leads to embryonic lethality [231].
The activation of the RAS pathway is a frequent feature of 
oncogenic transformation ([232], see also section on MLL-
AF4). The human family of RAS comprises three members 
that are activated in many cancer types (NRAS, KRAS, 
HRAS) (reviewed in Ref. [233]). These small GTPases 
can bind and hydrolyse GTP, and their activation requires a 
series of post-transcriptional modifications to ensure local-
isation to the plasma membrane. The first of these is the 
addition of a farnesyl group to a conserved cysteine resi-
due located in the CAAX motif of the C-terminal region. 
Without farnesylation, RAS remains in the cytoplasm and 
is inactive [234]. To determine if this was of therapeutic 
relevance, Reichert et al. investigated the effect of a farnesyl 
transferase inhibitor SCH66336, also known as lonafarnib, 
in the p190 BCR-ABL1 mouse model developed by Heis-
terkamp et al. [229, 235]. Mice that received SCH66336 
had a significantly better survival (up to 250 days) than the 
vehicle control group or the no treatment group (~56 days). 
After termination of treatment, some mice developed leu-
kaemia, suggesting that this drug cannot kill the leukaemia 
stem cells. The phase II clinical trial for lonafarnib is com-
pleted and could still benefit patients in combination with 
other drugs (NCT00034684).
The BCR-ABL1 fusion protein can interact with the p85α 
regulatory subunit of PI3K, an interaction vital for the pro-
liferation of BCR-ABL1-dependent leukaemia cells [236]. 
The resultant activation of the PI3K/AKT pathway, which 
also requires the SH2 domain of BCR-ABL1, results in an 
upregulation of BCL-2 and C-MYC [237]. Accordingly, 
deletion of both Pi3k subunits (Pik3r1 and Pik3r2) impaired 
Molecular processes involved in B cell acute lymphoblastic leukaemia 
1 3
the transformation of murine bone marrow cells with p190 
BCR-ABL1 and led to a loss of leukaemogenic potential 
[238]. An activation of the mTOR pathway independently 
of the PI3K/AKT pathway was also detected, suggesting that 
inhibiting both PI3K and mTOR (with the PI-103 inhibitor 
or similar), combined with the ABL inhibitor imatinib, could 
be a potential therapeutic avenue for Ph+ pre-B ALL. PI-103 
never reached clinical trial because of its high in vivo metab-
olism [239], but alternative drugs are being tested in phase I 
clinical trials such as NVP-BEZ235 (NCT01756118).
In 2010, Henry et al. compared the effect of BCR-ABL1 
on the B lymphoid potential of young and aged bone marrow 
cells [240]. Untransduced bone marrow cells showed a simi-
lar myeloid output, but the B lymphoid potential decreased 
with age. When transduced with p190 BCR-ABL1, cells 
of both ages displayed a higher engraftment and an expan-
sion of early B cell progenitors, pro-B cells, immature and 
mature B cells when old bone marrow cells were used as 
competitor cells. Furthermore, p190 BCR-ABL1-expressing 
cells showed a higher level of phosphorylated Akt, Stat5 and 
Erk. The use of old competitor cells in their transplantation 
experiments, along with young or old bone marrow cells 
transduced with p190 BCR-ABL1, led to the development 
of leukaemia. Their study suggested that young competitor 
cells may not be ideal when modelling B cell leukaemia 
using transplantation.
In 2011, Notta et al. described a Ph+ ALL xenograft sys-
tem that allowed the identification of multiple leukaemia-ini-
tiating clones in patients [241]. Recipients that were recon-
stituted with the predominant clone at diagnosis displayed 
a deletion of CDKN2A/B and fast disease. Interestingly, the 
xenograft clones constituted a population of leukaemia-ini-
tiating cells that did not always correspond to the sample at 
diagnosis. These results confirmed the heterogeneity of the 
leukaemia-initiating cell compartment and proposed that the 
engraftment is mostly due to more aggressive clones. This 
was also confirmed in another xenograft model by Ebinger 
et al. in 2016 [69].
Waldron et al. assessed the role of c-Myb and Bmi1 on 
the development of leukaemia in the p190 BCR-ABL1 
mouse model [242]. They found that the loss of one c-Myb 
allele is sufficient to slow p190 BCR-ABL1 leukaemogen-
esis and that this is partly due to a decrease in Bmi1 expres-
sion. This study showed that activation of the c-Myb–Bmi1 
axis is important for maintaining a high level of B-lymphoid 
clonogenic potential and ensuring disease progression of 
BCR-ABL1 pre-B ALL.
B cell ALL displays a differentiation arrest at the pro-B to 
pre-B stage and is associated with constitutive RAG activ-
ity, terminal deoxy-transferase expression and ongoing Ig 
heavy (IgH) chain rearrangement [243, 244]. In addition, the 
NF-κB transcription factor is constitutively active in ALL 
cells [245]. Ochodnicka-Mackovicova et al. investigated the 
relationship between the NF-κB and RAG pathways and 
noticed that the inhibition of NF-κB leads to an upregula-
tion of RAG expression and increased RAG-dependent DNA 
damage in a transformed mouse pre-B cell model [246]. In 
patients, a low expression of RAG1, RAG2 and TDT cor-
relates with higher expression of NF-κB. Since the inhibition 
of NF-κB can lead to increased RAG-dependent DNA dam-
age in patient leukaemia cells, this therapeutic avenue should 
be considered with extreme care. Rag-mediated recombina-
tion can lead to the deletion of Ikaros in BCR-ABL1+ pre-B 
ALL, which facilitates leukaemogenesis [219].
The IL7 receptor (IL7R) is crucially involved in lymphoid 
development and its loss leads to reduced lymphoid cellu-
larity in the peripheral blood [247]. Shochat et al. recently 
reported gain-of-function mutations in IL7R in paediatric 
B- and T-ALL through a serine-to-cysteine substitution 
(Ser185) in the extracellular region, or in-frame insertions 
and deletions in the transmembrane domain [248]. This 
resulted in the constitutive activation of the receptor and 
cytokine-independent growth of progenitor lymphoid cells. 
IL7R, once activated, can interact with JAK1 and JAK3 to 
phosphorylate and activate STAT5. The JAK/STAT pathway 
is often activated in leukaemia blasts of Ph+ pre-B ALL 
[249, 250]. P190 BCR-ABL1 can mediate the tyrosine phos-
phorylation of STAT members, and JAK1 and JAK2 have 
been found to be constitutively activated by mutations in the 
kinase and pseudokinase domains, which explains the sensi-
tivity of Ph+ leukaemia cells to JAK2 inhibitors [251, 252]. 
The biological features and therapeutic avenues of t(9;22) 
BCR-ABL1 pre-B ALL are presented in Fig. 4.
BCR‑ABL1‑like
In 2009, Den Boer et al. constructed a classifier based on 
gene expression to shed light on the 25% of pre-B ALL cases 
that are genetically unclassified [253]. This led to the iden-
tification of a BCR-ABL1-like phenotype in 15–50% of pae-
diatric cases that harbour deletions in IKZF1, PAX5, EBF1, 
TCF3 and VPREB1. The BCR-ABL1-like group was then 
confirmed in 30–40% of adult B-ALL cases [254]. In both 
age groups, this subtype is associated with a poor response 
to treatment through resistance to L-asparaginase and dau-
norubicin, and also a high risk of relapse [253]. In 2014, 
Roberts et al. published a genome profiling study aimed at 
identifying genetic alterations that could explain the poor 
prognosis [255]. They found a number of rearrangements of 
genes involved in tyrosine kinase signalling (ABL1, ABL2, 
CRFL2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, 
TSLP and TYK2) and mutations in FLT3, IL7R and SH2B3. 
Some of these rearrangements led to a constitutive activa-
tion of STAT5 and a sensitivity to dasatinib (ABL1, ABL2, 
CSF1R and PDGFRB fusion genes), ruxolitinib (EPOR and 
JAK2 rearrangements) and crizotinib (ETV6-NTRK3) [255, 
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256]. Furthermore, the use of tyrosine kinase inhibitors in 
BCR-ABL1-like patients and refractory cases has shown 
promising therapeutic results [257–259]. The phase II clini-
cal trial for dasatinib is completed (NCT00438854) while 
the recruitment has started for ruxolitinib (NCT02723994). 
Ex vivo analysis with primary patient cells are underway for 
crizotinib (NCT02551718).
Hyperdiploidy
Around 20–30% of paediatric and around 3% of adult B cell 
leukaemia are associated with a gain in chromosome num-
bers. There is evidence for a prenatal origin in some patients, 
but the frequency is low compared to other subtypes such as 
t(4;11) MLL-AF4 or t(12;21) ETV6-RUNX1 [260]. Patients 
respond very well to therapeutic drugs or DNA topoisomer-
ase inhibitors due to an overstimulation of the apoptotic 
response by hyperdiploid leukaemia cells [261, 262]. A sig-
nificant proportion of patients harbours mutations in FLT3 
(~25%), NRAS/KRAS (~15%) or PTNP11 genes (~10%), 
which are also involved in other paediatric pro- and pre-B 
ALL [263–265]. These mutations are mutually exclusive in 
most cases [266]. Other frequent abnormalities involve dele-
tions in loci of ETV6, CKDN2A, PAX5 and PAN3 [267].
Hypodiploidy
Hypodiploidy is a rare subset of B cell leukaemia in both 
children and adults (1–2%) and is associated with a very 
poor prognosis. The aetiology is not known, but the gene 
dosage or unmasking of recessive alleles could be part of the 
answer (as reviewed in Ref. [268]). Holmfeldt et al. recently 
described the genomic landscape of hypodiploid ALL using 
whole-genome and exome sequencing [269]. Around 71% 
of near-haploid patients (24–31 chromosomes) had muta-
tions in genes leading to the activation of receptor tyrosine 
kinases and Ras signalling, and 13% presented deletions and 
one frameshift mutation in IKZF3, a lymphoid transcription 
factor of the IKAROS family. They also found mutations 
in TP53 (~90%), IKZF2 (~36%) and RB1 (~41%) in low-
hypodiploid patients (32–39 chromosomes). All patients 
showed activation of Ras- and PI3K-signalling and were 
sensitive to PI3K inhibitors, highlighting a potential thera-
peutic avenue. A phase I clinical trial is underway for the 
dual PI3K/mTOR inhibitor NVP-BEX235 (NCT01756118), 
and the phase I trial for the PI3K inhibitor GDC-0941 is 
complete (NCT00876122).
Trisomy 4 and 10
Trisomy of chromosomes 4 and 10 accounts for 20–25% of 
paediatric pre-B ALL, but is very rare in adults (Table 1). It 
is associated with an extremely favourable 4-year event-free 
survival (~96%) compared to around 70% for patients with 
none or just one trisomy (~70%) [270].
Intrachromosomal amplification of chromosome 21
The involvement of chromosome 21 in leukaemia is pre-
sent in 2% of cases of paediatric and 11% of adult B-ALL 
cases (as reviewed in Ref. [271]). Furthermore, children 
with Down syndrome have a 10–12 fold higher chance of 
developing an acute leukaemia compared to children without 
Down syndrome (as reviewed in Ref. [272]). This can lead 
Fig. 4  t(9;22) BCR-ABL1 pre-B acute lymphoblastic leukaemia. 
This leukaemia depends on the hijack of signalling pathways, includ-
ing the constitutive activation of ABL kinase and the activation of 
PI3K/AKT/mTOR pathways. These can be targeted by inhibitors of 
ABL (imatinib), mutant forms of BCR-ABL1 (asciminib/ABL001 
and nilotinib) and PI3K/mTOR (PI-103 and NVP-BEZ235). The 
activation of RAS, IL7R, C-MYB/BMI-1 and the phosphorylation of 
JAK2 can also contribute to disease. RAS can be inhibited by lona-
farnib, a farnesyl transferase inhibitor, and ruxolitinib can inhibit 
JAK2 activity
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to an amplification of the Runx1 locus in a subset of patients 
[273]. It is associated with a poor outcome and requires more 
intensive chemotherapy (HR COG ALL protocols) [274].
Conclusion
In this review, we aimed at providing an updated report 
of the field of B cell leukaemia with a particular empha-
sis on infant/paediatric ALL. In both paediatric and adult 
patients, the transformation process is usually initiated by 
a chromosomal translocation, creating a fusion gene with 
aberrant activity. Some fusion genes will interfere at the 
transcriptional level (MLL-AF4, ETV6-RUNX1, E2A-
PBX1) whereas others will activate signalling pathways 
that promote oncogenesis (BCR-ABL1). The first stages of 
transformation will prime the cells to become pre-malignant 
(pre-leukaemia cells) by inducing a differentiation arrest 
during B cell development and the acquisition of stem cell 
features (e.g. upregulation of Hox genes). What we have 
learned from the numerous mouse models of pro/pre-B ALL 
is that additional events are necessary to boost the trans-
formation process and bring those pre-leukaemia cells to 
induce a full-blown leukaemia. These events include genetic 
mutations that inactivate key players of B cell development 
(e.g. Pax5, Ikaros, Ebf1) or inhibitors of apoptosis (e.g. 
BCL-2 and MCL-1). There may also be an activation of 
genes involved in cell division and proliferation (e.g. CDK6, 
phosphorylation of PLCγ2). We are only starting to iden-
tify and understand the impact of co-drivers on pro/pre-B 
ALL, and these co-drivers can lead to the development of 
novel therapeutic avenues. For future studies, it will also be 
important to include external factors that can recapitulate 
the human environment. For example, an overstimulation of 
the immune response can lead to B cell leukaemia in Pax5 
haploinsufficient mice, whereas a clean environment does 
not lead to disease. Similar findings could be true for other 
factors (e.g. pesticides). It is also essential to understand 
the role of these mechanisms specifically in leukaemia stem 
cells as relapse from these therapy-resistant cells is a major 
clinical problem.
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